Ken J Ishii Selected Research

CPG-oligonucleotide

7/2022	CpG ODN (K3)-toll-like receptor 9 agonist-induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I study.
12/2018	The protective effects of nasal PcrV-CpG oligonucleotide vaccination against Pseudomonas aeruginosa pneumonia.
1/2018	DAMP-Inducing Adjuvant and PAMP Adjuvants Parallelly Enhance Protective Type-2 and Type-1 Immune Responses to Influenza Split Vaccination.
10/2015	CpG oligodeoxynucleotides potentiate the antitumor activity of anti-BST2 antibody.
9/2015	[Development of Nucleic Acid-Based Adjuvant for Cancer Immunotherapy].
4/2015	TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN.
8/2005	CpG-activated Thy1.2+ dendritic cells protect against lethal Listeria monocytogenes infection.
1/2005	CpG oligodeoxynucleotides enhance neonatal resistance to Listeria infection.
6/2004	CpG oligodeoxynucleotides improve the survival of pregnant and fetal mice following Listeria monocytogenes infection.
2/2004	Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ken J Ishii Research Topics

Disease

35	Infections 01/2022 - 07/2002
31	Neoplasms (Cancer) 07/2022 - 12/2003
18	Malaria 01/2022 - 07/2002
16	Human Influenza (Influenza) 01/2022 - 07/2006
15	Bites and Stings (Sting) 01/2022 - 12/2011
15	Inflammation (Inflammations) 01/2020 - 08/2002
11	Communicable Diseases (Infectious Diseases) 01/2022 - 04/2004
7	Pneumonia (Pneumonitis) 12/2019 - 10/2004
7	Virus Diseases (Viral Diseases) 01/2016 - 10/2005
6	Autoimmune Diseases (Autoimmune Disease) 01/2021 - 02/2005
5	Hypersensitivity (Allergy) 01/2017 - 06/2010
3	Melanoma (Melanoma, Malignant) 01/2008 - 05/2006
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022 - 08/2016
2	Atopic Dermatitis (Atopic Eczema) 01/2021 - 06/2015
2	Coinfection 11/2019 - 02/2011
2	Porcine Reproductive and Respiratory Syndrome (PRRS) 11/2019 - 09/2008
2	Asthma (Bronchial Asthma) 01/2019 - 04/2013
2	Contact Dermatitis (Eczema, Contact) 01/2018 - 11/2014
2	Bacterial Infections (Bacterial Infection) 01/2017 - 02/2011
2	Ischemia 12/2015 - 07/2013
2	Lymphoma (Lymphomas) 04/2015 - 04/2014
2	Parasitemia 09/2010 - 01/2007
2	Cerebral Malaria 03/2010 - 01/2007
2	Vesicular Stomatitis 08/2009 - 08/2007
2	Arthritis (Polyarthritis) 06/2003 - 08/2002
1	Lung Neoplasms (Lung Cancer) 07/2022
1	Necrosis 01/2022

Drug/Important Bio-Agent (IBA)

38	VaccinesIBA 01/2022 - 01/2004
21	AntigensIBA 01/2022 - 07/2006
17	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 08/2002
14	OligodeoxyribonucleotidesIBA 07/2022 - 08/2002
12	CPG-oligonucleotideIBA 07/2022 - 12/2003
11	CytokinesIBA 11/2019 - 05/2004
10	Vaccine AdjuvantsIBA 01/2022 - 04/2004
9	InterferonsIBA 01/2021 - 10/2005
9	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2021 - 10/2004
9	Interferon Type IIBA 01/2019 - 07/2006
8	LigandsIBA 01/2022 - 04/2014
8	Proteins (Proteins, Gene)FDA Link 01/2022 - 05/2006
8	Nucleic AcidsIBA 01/2018 - 11/2005
7	hemozoinIBA 06/2017 - 07/2002
6	Interleukin-33IBA 10/2020 - 02/2012
6	AntibodiesIBA 01/2020 - 01/2011
6	Immunoglobulin G (IgG)IBA 01/2019 - 09/2010
5	K3-SPGIBA 01/2022 - 08/2016
5	Hemagglutinins (Hemagglutinin)IBA 11/2019 - 03/2015
5	cyclic guanosine monophosphate-adenosine monophosphateIBA 11/2019 - 04/2015
4	Peptides (Polypeptides)IBA 01/2021 - 02/2009
4	InflammasomesIBA 01/2020 - 03/2010
4	Antiviral Agents (Antivirals)IBA 01/2019 - 01/2006
4	AllergensIBA 01/2017 - 02/2004
4	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2016 - 05/2006
4	DNA VaccinesIBA 07/2013 - 07/2006
3	Cancer VaccinesIBA 01/2022 - 09/2015
3	Interleukin-12 (IL 12)IBA 01/2022 - 04/2015
3	Toll-Like Receptor 9IBA 01/2022 - 08/2005
3	Pattern Recognition ReceptorsIBA 11/2019 - 09/2008
3	Immunoglobulin E (IgE)IBA 01/2019 - 06/2015
3	Phosphotransferases (Kinase)IBA 07/2016 - 12/2011
3	RNA (Ribonucleic Acid)IBA 03/2015 - 05/2006
3	AluminumIBA 01/2013 - 09/2010
2	Phosphates (Orthophosphate)IBA 07/2022 - 05/2009
2	9 alpha,11 alpha,15 alpha- trihydroxy- 16- phenoxy- 17,18,19,20- tetranorprosta- 4,5,13- trienoic acid (TPT)IBA 01/2022 - 01/2017
2	Topotecan (Hycamtin)FDA LinkGeneric 01/2022 - 01/2017
2	Messenger RNA (mRNA)IBA 01/2022 - 01/2020
2	Therapeutic UsesIBA 01/2021 - 02/2004
2	Carrier Proteins (Binding Protein)IBA 01/2020 - 02/2014
2	EpitopesIBA 01/2019 - 02/2017
2	Influenza Vaccines (Influenza Vaccine)FDA Link 01/2019 - 01/2016
2	Biomarkers (Surrogate Marker)IBA 01/2018 - 01/2014
2	Imiquimod (Aldara)FDA LinkGeneric 01/2018 - 01/2018
2	Pathogen-Associated Molecular Pattern MoleculesIBA 01/2018 - 01/2012
2	Poly I-CIBA 01/2018 - 02/2011
2	Interleukin-23 (Interleukin 23)IBA 01/2018 - 01/2018
2	Interleukin-17 (Interleukin 17)IBA 01/2018 - 01/2018
2	Hemoglobins (Hemoglobin)IBA 06/2017 - 01/2005
2	aluminum sulfate (alum)IBA 02/2017 - 01/2016
2	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 01/2017 - 03/2010
2	Antineoplastic Agents (Antineoplastics)IBA 01/2017 - 04/2015
2	Neoplasm Antigens (Tumor Antigens)IBA 08/2016 - 09/2015
2	Biological ProductsIBA 07/2016 - 01/2014
2	CyclodextrinsIBA 01/2016 - 03/2015
2	Retinaldehyde (Retinal)IBA 12/2015 - 07/2013
2	Toll-Like Receptor 4IBA 12/2015 - 07/2013
2	Interferon Regulatory Factor-3 (Interferon Regulatory Factor 3)IBA 12/2015 - 02/2014
2	B-Form DNA (B-DNA)IBA 04/2015 - 01/2006
2	Hydroxyl RadicalIBA 01/2013 - 09/2010
2	Interleukin-13IBA 02/2012 - 12/2003
2	A-Form DNA (A-DNA)IBA 12/2011 - 07/2006
2	Heme (Haem)IBA 01/2010 - 01/2005
2	ChemokinesIBA 08/2009 - 10/2004
2	RNA Helicases (RNA Helicase)IBA 01/2008 - 10/2005
2	Bacterial DNAIBA 12/2003 - 08/2002
1	GuanineIBA 07/2022
1	Single-Stranded DNA (DNA, Single Stranded)IBA 07/2022
1	CytosineIBA 07/2022

Therapy/Procedure

9	Therapeutics 01/2022 - 12/2003
8	Immunotherapy 07/2022 - 12/2003
2	Intravenous Injections 01/2022 - 08/2016
2	Intranasal Administration 01/2020 - 02/2011